))
Season 2 - Episode 12: Immune checkpoint inhibitors and the heart - HDL, HDL therapies and cardiovascular risk
Manage episode 409292411 series 3559418
Контент предоставлен European Society of Cardiology. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией European Society of Cardiology или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.
This episode covers:
- Cardiology This Week: A concise summary of recent studies
- Immune checkpoint inhibitors and the heart
- HDL, HDL therapies and cardiovascular risk
- Diagnostics Made Easy: the FBI syndrome
Host: Susanna Price
Guests: Carlos Aguiar, Alexander Lyon, Francois Mach
Want to watch that episode? Go to: https://esc365.escardio.org/event/1147
Disclaimer
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
Declarations of interests
Stephan Achenbach, Francois Mach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.
Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.
Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic.
Alexander Lyon has declared to receive speaker, advisory board or consultancy fees and/or research grants from Janssens-Cilag Ltd, Astellas Pharma, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd.
Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.
42 эпизодов
Поделиться
